KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Asset Writedowns and Impairment (2016 - 2025)

Neogenomics (NEO) has disclosed Asset Writedowns and Impairment for 12 consecutive years, with $12.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 10555.56% year-over-year to $12.5 million, compared with a TTM value of $27.8 million through Dec 2025, up 10492.75%, and an annual FY2025 reading of $27.8 million, up 6067.33% over the prior year.
  • Asset Writedowns and Impairment was $12.5 million for Q4 2025 at Neogenomics, up from $7.1 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $12.5 million in Q4 2025 and bottomed at -$3000.0 in Q4 2023.
  • Average Asset Writedowns and Impairment over 4 years is $3.0 million, with a median of $727500.0 recorded in 2022.
  • The sharpest move saw Asset Writedowns and Impairment plummeted 100.42% in 2023, then soared 10555.56% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $718000.0 in 2022, then tumbled by 100.42% to -$3000.0 in 2023, then skyrocketed by 4000.0% to $117000.0 in 2024, then skyrocketed by 10555.56% to $12.5 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for NEO at $12.5 million in Q4 2025, $7.1 million in Q3 2025, and $8.2 million in Q2 2025.